VERA
HealthcareVera Therapeutics, Inc. · Biotechnology · $2B
What is Vera Therapeutics, Inc.?
Vera Therapeutics is a clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Headquartered in Brisbane, California, it was incorporated in 2016.
Vera Therapeutics advances pipeline candidates targeting immunological conditions. Its lead asset, atacicept, is a self-administered fusion protein in late-stage clinical trials for IgA nephropathy. The company also develops MAU868, a monoclonal antibody targeting BK viremia infections, currently in Phase 2 trials. Revenue generation depends on successful clinical outcomes and eventual commercialization.
Vera Therapeutics was incorporated in 2016 and is headquartered in Brisbane, California.
- Atacicept — subcutaneous fusion protein for IgA nephropathy
- MAU868 — monoclonal antibody for BK viremia
- Immunological disease pipeline development
Is VERA a Good Stock to Buy?
UQS Score rates VERA as Poor overall, reflecting the early-stage nature of its pipeline and the financial profile typical of pre-revenue biotechs.
Among the five pillars, Risk stands out as the relative bright spot, suggesting the company maintains a manageable near-term financial structure compared to some peers at a similar development stage.
Quality, Moat, and Growth all register as Weak, consistent with a company that has no commercial products yet. Valuation is rated Elevated, meaning the current price reflects significant future expectations.
See the complete pillar breakdown and full financial metrics by signing up for a Pro account at UQS Score. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does VERA pay dividends?
No — Vera Therapeutics, Inc. does not currently pay a dividend.
Vera Therapeutics does not pay a dividend. As a clinical-stage company with no commercial revenue, available capital is directed toward research, clinical trials, and pipeline advancement rather than shareholder distributions.
When does VERA report earnings?
Vera Therapeutics reports financial results on a quarterly cadence, standard for US-listed public companies.
As a pre-revenue biotech, quarterly reports focus on cash runway, pipeline milestones, and operating expenses rather than sales growth. Clinical trial progress tends to be the primary driver of investor attention each reporting period.
For the most recent quarter's results and upcoming reporting dates, visit Vera Therapeutics' investor relations page directly.
VERA Price History
+132.2% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Vera Therapeutics, Inc.?
Based on Vera Therapeutics, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does Vera Therapeutics do?
Vera Therapeutics is a clinical-stage biotech developing treatments for serious immunological diseases. Its lead program, atacicept, targets IgA nephropathy, while MAU868 addresses BK viremia infections. Neither product is yet commercially approved.
Does VERA pay dividends?
No. Vera Therapeutics does not pay a dividend. Pre-revenue biotechs typically reinvest all available capital into clinical development rather than returning cash to shareholders.
When does VERA report earnings?
Vera Therapeutics follows a standard quarterly reporting schedule. For exact dates, check the company's investor relations page, as our data source does not cover upcoming earnings dates.
Is VERA a good stock to buy?
UQS Score rates VERA as Poor overall. The rating reflects weak Quality, Moat, and Growth scores alongside an Elevated Valuation. Investors should weigh clinical trial risk carefully. The full pillar breakdown is available to Pro members.
Is VERA overvalued?
UQS Score's Valuation pillar for VERA is rated Elevated, suggesting the current market price embeds significant expectations around pipeline success — a common dynamic for clinical-stage biotechs with no commercial revenue yet.
Is VERA a long-term quality investment?
From a long-term quality standpoint, VERA's UQS profile is Poor, with Weak scores across Quality, Moat, and Growth pillars. Long-term outcomes depend heavily on clinical trial results and eventual regulatory approval. Pro members can view the complete analysis.
What is VERA's market cap bracket?
Vera Therapeutics is classified as a mid-cap stock. For a clinical-stage biotech, this reflects market expectations around its pipeline potential rather than current revenues.
What sector does VERA belong to?
Vera Therapeutics operates in the Healthcare sector, specifically within clinical-stage biotechnology. The company focuses on immunological diseases, a specialized niche within the broader biotech landscape.
Unlock Full VERA Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score pillar breakdown across all five dimensions
- ✓Access full financial metrics and trend data
- ✓Compare VERA against sector peers on quality and risk
- ✓Get the complete analyst-style view available to Pro members
Pro Analysis
VERA — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 12, 2026 | 14.4 | 0.0 | 13.0 | 0.0 | 74.3 | 0.0 | +4.2 |
| May 9, 2026 | 10.2 | 0.0 | 13.0 | 0.0 | 46.2 | 0.0 | -3.0 |
| Apr 2, 2026 | 13.2 | 0.0 | 13.0 | 0.0 | 66.2 | 0.0 | — |
VERA — Pillar Breakdown
Quality
— 0.0/100 (25%)Vera Therapeutics, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 0.0/100 (20%)Vera Therapeutics, Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 74.3/100 (15%)Vera Therapeutics, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Vera Therapeutics, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 13/100 (25%)Vera Therapeutics, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for VERA.
Score Composition
Financial Data
More Stock Analysis
How is the VERA UQS Score Calculated?
The UQS (Unified Quality Score) for Vera Therapeutics, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Vera Therapeutics, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Vera Therapeutics, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.